Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017173101) COMBINATION THERAPY FOR NEUROBLASTOMA USING MDA-7/IL-24 WITH THERAPEUTIC AGENTS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/173101 International Application No.: PCT/US2017/025056
Publication Date: 05.10.2017 International Filing Date: 30.03.2017
IPC:
A61K 38/20 (2006.01) ,A61K 48/00 (2006.01) ,A61P 35/00 (2006.01) ,C07K 14/54 (2006.01) ,C12N 15/86 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
19
Cytokines; Lymphokines; Interferons
20
Interleukins
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
52
Cytokines; Lymphokines; Interferons
54
Interleukins (IL)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79
Vectors or expression systems specially adapted for eukaryotic hosts
85
for animal cells
86
Viral vectors
Applicants:
VIRGINIA COMMONWEALTH UNIVERSITY [US/US]; 800 E. Leigh St. Richmond, VA 232908, US
Inventors:
FISHER, Paul, B.; US
BHOOPATHI, Praveen; US
EMDAD, Luni; US
DAS, Swadesh, K.; US
SARKAR, Devanand; US
Agent:
CHAN, Albert, Wai-Kit; US
Priority Data:
62/315,12630.03.2016US
Title (EN) COMBINATION THERAPY FOR NEUROBLASTOMA USING MDA-7/IL-24 WITH THERAPEUTIC AGENTS
(FR) POLYTHÉRAPIE POUR LE TRAITEMENT DU NEUROBLASTOME À L'AIDE DE MDA-7/IL-24 AVEC DES AGENTS THÉRAPEUTIQUES
Abstract:
(EN) This invention discloses methods of treating neuroblastoma using Ad.5/3-CTV. In one embodiment, the present invention provides a method of treating neuroblastoma in a subject using Ad.5/3-CTV. In another embodiment, the present invention provides a method of inhibiting the growth of a neuroblastoma tumor using Ad.5/3-CTV. In one embodiment, the present invention provides a method of inhibiting the growth of a neuroblastoma cell using Ad.5/3-CTV. In yet another embodiment, the present invention provides a method of inducing apoptosis or toxic autophagy in a neuroblastoma cell using Ad.5/3-CTV. In one embodiment, the present invention provides a method of maintaining remission of neuroblastoma in a subject which has been treated for neuroblastoma. In one embodiment, the methods described herein further comprise a step of administering to the subject or cell a therapeutic agent selected from the group consisting of poly[IC]-PEI, doxorubicin, and any other therapeutic agents that promote toxic autophagy and/or apoptosis.
(FR) Cette invention concerne des procédés de traitement du neuroblastome à l'aide d'Ad.5/3-CTV. Dans un mode de réalisation, la présente invention concerne un procédé de traitement du neuroblastome chez un sujet à l'aide d'Ad.5/3-CTV. Dans un autre mode de réalisation, la présente invention concerne un procédé d'inhibition de la croissance d'une tumeur de neuroblastome à l'aide d'Ad.5/3-CTV. Dans un mode de réalisation, la présente invention concerne un procédé d'inhibition de la croissance d'une cellule de neuroblastome à l'aide d'Ad.5/3-CTV. Dans encore un autre mode de réalisation, la présente invention concerne un procédé d'induction de l'apoptose ou de l'autophagie toxique dans une cellule de neuroblastome à l'aide d'Ad.5/3-CTV. Dans un mode de réalisation, la présente invention concerne un procédé de maintien de rémission de neuroblastome chez un sujet qui a été traité pour neuroblastome. Dans un mode de réalisation, les procédés décrits ici comprennent en outre une étape d'administration au sujet ou à une cellule d'un agent thérapeutique choisi dans le groupe constitué par poly[IC]-PEI, la doxorubicine, et tout autre agent thérapeutique qui favorise l'autophagie toxique et/ou l'apoptose.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)